MedTrace Logo

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

NCT03983993 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-01-05

Study results available
· View outcomes & findings →

Summary

This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and panitumumab may work better in treating patients with colorectal cancer.

Conditions

  • Advanced Microsatellite Stable Colorectal Carcinoma
  • Metastatic Microsatellite Stable Colorectal Carcinoma
  • Microsatellite Stable
  • RAS Wild Type
  • Stage IV Colorectal Cancer AJCC v8
  • MSI-H Colorectal Cancer

Interventions

DRUG

Niraparib

Given PO

BIOLOGICAL

Panitumumab

Given IV

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Olatunji Alese, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2023-05-17
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03983993 on ClinicalTrials.gov